Philip Astley-Sparke
CIK: 0001376491
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Aug 20, 2026REPL
Replimune Group, Inc.
Gift(G)Direct50K shares- - Jun 16, 2026ENGN
enGene Therapeutics Inc.
Award(A)DirectStock Option (Right to Buy)
31K shares- - May 18, 2026REPL
Replimune Group, Inc.
Sale(S)Direct17.7K shares at avg. $5.08$90K - Apr 1, 2026REPL
Replimune Group, Inc.
Award(A)Direct50K shares- - Feb 18, 2026REPL
Replimune Group, Inc.
Gift(G)Direct25K shares- - Jul 8, 2025ENGN
enGene Holdings Inc.
Award(A)DirectStock Option (Right to Buy)
45K shares- - May 20, 2025REPL
Replimune Group, Inc.
Sale(S)Direct32.3K shares at avg. $8.06$260K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 20, 2026 |  REPL Replimune Group, Inc. | Gift(G) | 50,000 | - | $0 | Direct |
| Jun 16, 2026 |  ENGN enGene Therapeutics Inc. | Award(A) Stock Option (Right to Buy) | 31,000 | - | - | Direct |
| May 18, 2026 | REPL Replimune Group, Inc. | Sale(S) | 17,657 | $5.08 | $89,698 | Direct |
| Apr 1, 2026 | REPL Replimune Group, Inc. | Award(A) | 50,000 | - | $0 | Direct |
| Feb 18, 2026 | REPL Replimune Group, Inc. | Gift(G) | 25,000 | - | $0 | Direct |
| Jul 8, 2025 | ENGN enGene Holdings Inc. | Award(A) Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| May 20, 2025 | REPL Replimune Group, Inc. | Sale(S) | 32,279 | $8.06 | $260,169 | Direct |
1-7 of 7 transactions
About Astley-Sparke Philip
Astley-Sparke Philip (SEC CIK 0001376491) files insider reports with the SEC as Director of Replimune Group, Inc. (REPL) and Director of enGene Therapeutics Inc. (ENGN).
Signal8 holds 8 ownership filings by Astley-Sparke Philip (1 Form 3, 7 Form 4), filed between May 22, 2025 and Aug 24, 2026. Those filings report 7 transactions, from May 20, 2025 to Aug 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Astley-Sparke Philip's filings is in WOBURN, MA.
Recent filings by Astley-Sparke Philip
- Aug 20, 2026: Gift of REPL shares (Form 4, code G).
- Jun 16, 2026: Grant or award of ENGN derivative securities (Form 4, code A).
- May 18, 2026: Open-market sale of REPL shares (Form 4, code S).
- Apr 1, 2026: Grant or award of REPL shares (Form 4, code A).
- Feb 18, 2026: Gift of REPL shares (Form 4, code G).
Other insiders filing for Replimune Group, Inc. (REPL)
- Hill Emily Luisa, Chief Financial Officer
- Patel Sushil, Chief Executive Officer
- Xynos Konstantinos, Chief Medical Officer
- Schwendenman Andrew, Chief Accounting Officer
- BAKER BROS. ADVISORS LP, Director
- Sarchi Christopher, Chief Commercial Officer